Changes in Somatostatin Receptor mRNA Levels by G Protein Mutation in GH3 Cells Which Show Responsiveness to Growth Hormone-Releasing Hormone.
10.3803/jkes.2005.20.4.323
- Author:
Eun Hee KIM
1
;
Sook Jin SOHN
;
Min A LEE
;
Sang Hee SEO
;
Sung Hee JU
;
Dahm LEE
;
Hyun Ju CHUNG
;
Jee Chang JUNG
;
Seung Joon PARK
Author Information
1. Department of Pharmacology, Kyunghee University School of Medicine, Seoul 130-701, Korea.
- Publication Type:In Vitro ; Original Article
- Keywords:
Somatostatin receptor;
G protein mutation;
GHRH receptor;
GH3 cells;
cAMP
- MeSH:
Blotting, Northern;
Blotting, Western;
DNA, Complementary;
Growth Hormone-Releasing Hormone*;
GTP-Binding Proteins*;
Humans;
Octreotide;
Oncogenes;
Pituitary Neoplasms;
Plasmids;
Receptors, Somatostatin*;
RNA, Messenger*;
Somatostatin*
- From:Journal of Korean Society of Endocrinology
2005;20(4):323-333
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUNDS: GH3 cells lack growth hormone(GH)-releasing hormone(GHRH) receptors. In this study, GH3 cells permanently transfected with human GHRH receptor cDNA(GH3-GHRHR cells), were established in order to examine the effects of GHRH and G protein mutation(gsp oncogene) on the levels of somatostatin receptor mRNA. METHODS: GH3 cells were permanently transfected with a plasmid expressing human GHRH receptor cDNA. The GHRH receptor mRNA was detected by RT-PCR. The responsiveness to GHRH was evaluated using a GHRH binding assay, Western blot analysis, Northern blot analysis, and measurements of the intracellular cAMP levels and GH release. Cells were transiently transfected with the gsp oncogene, and then treated with GHRH or octreotide for 4h. The sst1 and sst2 mRNA levels were measured using real-time RT-PCR analyses. RESULTS: GHRH receptor mRNA was detected in the GH3 cells permanently transfected with human GHRH receptor cDNA. The GHRH binding assay showed that GHRH was bound to the GH3-GHRHR cells. The GHRH treatment increased the intracellular cAMP levels, GH release, GH mRNA levels, and MAPK activity, as well as the levels of sst1 and sst2 mRNA. Transient expression of the gsp oncogene for 48h increased the cAMP, GH release, and levels of sst1 and sst2 mRNA. In the gsp-transfected GH3-GHRHR cells, GHRH stimulation resulted in decreases in the magnitude of the increase in the levels of sst1 and sst2 mRNA compared to those transfected with a control vector. Octreotide treatment did not alter the levels of sst1 and sst2 mRNA in either the control or gsp-transfected cells. CONCLUSION: These results suggest that GH3 cells permanently transfected with the GHRH receptor are useful in the in vitro studies on the actions of GHRH. The gsp oncogene was shown to increases the levels of sst1 and sst2 mRNA in GH3 cells, but these findings are unlikely to be the major mechanism by which gsp-positive pituitary tumors show a greater response to somatostatin. The discrepancy between the in vivo and these in vitro results should be examined further.
